Project Director Respiratory Diseases, SGS Life Science Clinical Research,
Antwerpen
Belgium
Research Article
Innovations in Outcomes and Designs of Clinical Trials for Respiratory Drug Development
Author(s): Lins RLLins RL
Clinical trials for the development of respiratory drugs have for years been reliant upon measurements of physiologic tests, combined with the use of questionnaires. New drugs were mostly administered by inhalation and increasingly in fixed combinations. However, these lung function tests have a lack of sensitivity for patient-relevant clinical outcomes. Moreover, new insights in phenotypes and endotypes of these diseases in the basic mechanisms and the discovery of new targets for therapy, have led to the need for a more personalized patient-centered approach and precision medicine. In recent years, a great number of techniques have been proposed but some need further validation. These include fractional exhaled nitric oxide, health-related quality of life and the use of biomarkers like blood and sputum eosinophils and neutrophils, IgE, sIgE, periostin, copeptin and specific cytokine.. Read More»
DOI:
10.4172/2472-1247.1000127
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 